The latest big-ticket acquisition in the healthcare industry has closed. On Tuesday, Bristol Myers Squibb (NYSE:BMY) announced that its buyout of heart medication specialist MyoKardia has been finalized; the latter company is now a fully owned subsidiary, with its stock being delisted from the Nasdaq.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,